Developing anti-helminth vaccines for people and cattle: (For)seeing the health approach in action.
作者信息
Tendler Miriam, Savino Wilson, Almeida Marilia Sirianni Dos Santos
机构信息
Laboratory of Anti-Helminth Vaccine Research and Development, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Laboratory on Thymus Research, Brazilian National Institute of Science and Technology on Neuroimmunomodulation, Rio de Janeiro Research Network on Neuroinflammation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
出版信息
One Health. 2023 Aug 18;17:100616. doi: 10.1016/j.onehlt.2023.100616. eCollection 2023 Dec.
Abstract
摘要
相似文献
1
Developing anti-helminth vaccines for people and cattle: (For)seeing the health approach in action.
One Health. 2023 Aug 18;17:100616. doi: 10.1016/j.onehlt.2023.100616. eCollection 2023 Dec.
2
The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine.
Acta Trop. 2008 Nov-Dec;108(2-3):263-6. doi: 10.1016/j.actatropica.2008.09.002. Epub 2008 Sep 11.
3
Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge.
Infect Immun. 2004 Jun;72(6):3336-43. doi: 10.1128/IAI.72.6.3336-3343.2004.
4
Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate.
Biochim Biophys Acta. 2009 Apr;1794(4):655-62. doi: 10.1016/j.bbapap.2008.12.010. Epub 2008 Dec 25.
5
Co-administration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone.
Microbes Infect. 2006 Aug;8(9-10):2509-16. doi: 10.1016/j.micinf.2006.06.008. Epub 2006 Jul 24.
6
Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection.
Exp Parasitol. 2014 Oct;145:51-60. doi: 10.1016/j.exppara.2014.07.010. Epub 2014 Aug 1.
7
Sm14 gene expression in different stages of the Schistosoma mansoni life cycle and immunolocalization of the Sm14 protein within the adult worm.
Braz J Med Biol Res. 2002 Mar;35(3):377-81. doi: 10.1590/s0100-879x2002000300014.
8
Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model.
BMC Infect Dis. 2015 Mar 24;15:147. doi: 10.1186/s12879-015-0906-z.
9
Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice.
Infect Immun. 2004 Oct;72(10):5931-7. doi: 10.1128/IAI.72.10.5931-5937.2004.
10
Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis.
Microbes Infect. 2005 Feb;7(2):204-12. doi: 10.1016/j.micinf.2004.10.012. Epub 2005 Jan 19.
本文引用的文献
1
Development of the Sm14/GLA-SE Schistosomiasis Vaccine Candidate: An Open, Non-Placebo-Controlled, Standardized-Dose Immunization Phase Ib Clinical Trial Targeting Healthy Young Women.
Vaccines (Basel). 2022 Oct 15;10(10):1724. doi: 10.3390/vaccines10101724.
2
Covid-19 pandemic, R&D, vaccines, and the urgent need of UBUNTU practice.
Lancet Reg Health Am. 2021 Sep;1:100020. doi: 10.1016/j.lana.2021.100020. Epub 2021 Jul 24.
3
Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep.
Vet Res. 2021 Jan 28;52(1):13. doi: 10.1186/s13567-021-00895-0.
4
Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults.
Vaccine. 2016 Jan 20;34(4):586-594. doi: 10.1016/j.vaccine.2015.10.027. Epub 2015 Nov 10.
5
Immunomodulatory molecules of Fasciola hepatica: candidates for both vaccine and immunotherapeutic development.
Vet Parasitol. 2013 Aug 1;195(3-4):272-85. doi: 10.1016/j.vetpar.2013.04.008. Epub 2013 Apr 6.
6
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
Lancet. 2012 Dec 15;380(9859):2197-223. doi: 10.1016/S0140-6736(12)61689-4.
7
Evaluation of local immune response to Fasciola hepatica experimental infection in the liver and hepatic lymph nodes of goats immunized with Sm14 vaccine antigen.
Mem Inst Oswaldo Cruz. 2010 Aug;105(5):698-705. doi: 10.1590/s0074-02762010000500017.
8
Understanding triclabendazole resistance.
Exp Mol Pathol. 2007 Apr;82(2):104-9. doi: 10.1016/j.yexmp.2007.01.009. Epub 2007 Feb 15.
9
Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14.
Parasite Immunol. 2003 Mar;25(3):135-7. doi: 10.1046/j.1365-3024.2003.00619.x.
10
Schistosomiasis: from risk assessment to control.
Trends Parasitol. 2002 Jul;18(7):309-14. doi: 10.1016/s1471-4922(02)02301-2.
Zotero 插件